Hangzhou Diagens Biotechnology Co., Ltd. Class H
HHKEX:2526205.40
HKD
-18.60
(-8.30%)
ISIN
CNE100007JC7
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ning Song
- Full Time Employees
- 166
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Room 101 Hangzhou ZH China 311100
- IPO Date
- Mar 30, 2026
- Website
- diagens.com
- Similar Companies
- Business
- Hangzhou Diagens Biotechnology Co., Ltd. is a China-based company focused on medical imaging products and services for the medical device sector, with a portfolio that includes AI-driven imaging software, imaging hardware, and related data analytics capabilities; the company operates through multiple business lines and serves hospitals, medical institutions, and research organizations in its geographic footprint, primarily within China, with broader Asia-Pacific outreach, leveraging licensing of its iMedImage foundation model via the iMedMaaS platform to generate licensing fees and related services; it develops and markets core products such as AI AutoVision, a chromosome karyotype assisted diagnostic system; MetaSight automatic cell microscopic image scanning system; and KayoFlow automatic cell harvester, along with associated software, workflow solutions, and software-as-a-service offerings; the company integrates its imaging software with hardware solutions, provides clinical support and consulting services, and offers pre- and post-sale maintenance and technical services. Headquarters are in Hangzhou, China, and the company was founded in the 2010s (founding year publicly cited as around 2014–2016 in various market profiles); its corporate structure includes subsidiaries and potential ties to parent or listed vehicles, with its ticker 2526.HK (Hangzhou Diagens Biotechnology) representing its listed status on the Hong Kong Exchange; latest major changes in the period include strategic partnerships and product expansions around AI-enabled imaging platforms, licensing collaborations, and potential expansions of its iMedImage ecosystem, as well as ongoing refinements to its end-to-end workflow and data processing capabilities to support broader commercial deployment.